PACB vs SNN Stock Comparison
SNN currently leads PACB in this stock comparison, with AIQ scores of 70 vs 48. The clearest difference is value, while PACB has the stronger momentum profile.
What is the main difference between PACB and SNN?
SNN leads the current stock comparison as Smith & Nephew plc, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Pacific Biosciences of California, Inc. vs Smith & Nephew plc
SNN leads
SNN leads by 22 AIQ points, primarily on Value and Risk Resilience, and the lead has widened from 19 points over 30 sessions.
Stable: 4 of 6 evidence groups support SNN, and its lead is widening.
Pacific Biosciences of California, Inc.
Smith & Nephew plc
The Algovestiq AIQ Score currently favors SNN over PACB, 70 versus 48 as of Nov 18, 2026. SNN's advantage is driven primarily by stronger value and risk resilience, while PACB holds the stronger momentum profile. SNN also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor SNN today, and the comparison is rated Stable on stability. SNN lead: Strengthening — the AIQ differential moved from 19 to 22 points over 30 sessions.
Compare Pacific Biosciences of California, Inc. and Smith & Nephew plc across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare PACB and SNN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value23 vs 79SNN +56
- Risk Resilience24 vs 75SNN +51
- Quality32 vs 73SNN +41
- Momentum84 vs 60PACB +24
4 of 6 evidence groups favor SNN. SNN’s edge is concentrated in value and risk resilience; PACB keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
No factor moved materially.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
SNN's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — PACB and SNN both carry a full feed there.
The central trade-off
SNN (Smith & Nephew plc): the stronger current systematic profile, led by value and risk resilience.
PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, fundamentals, technicals — but at materially higher volatility, 114.1% against 38.7%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
SNNSNN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PACBPACB on combined revenue and EPS growth.
Value
SNNSNN on the peer-relative Value factor, by 56 points.
Momentum
PACBPACB on the Momentum factor, by 24 points.
Lower downside
SNNSNN on Risk Resilience, by 51 points.
Analyst upside
SNNSNN on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | PACB | SNN | Note |
|---|---|---|---|
| Implied upside to target | +5.2% | +11.7% | SNN has more room |
| Target dispersion | +59.7% | 0% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 8 | 6 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor SNN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | SNN | 48 vs 70 |
| Fundamentals | PACBon balance | revenue growth 4% vs -3.3%; EPS growth 14.3% vs -7.7%; TTM ROE 61.7% vs 5.8%; gross margin 34.5% vs 68.2%; operating margin -99.6% vs 16.7% — PACB takes 3 of 5 decided legs, not all of them |
| Valuation | SNN | Value 23 vs 79 |
| Technicals | PACB | Price vs 50-day -8.7% vs 5.5%; vs 200-day 22.4% vs 1% |
| Risk Resilience | SNN | Risk Resilience 24 vs 75 |
| Analyst expectations | SNN | Target upside 5.2% vs 11.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PACB and SNN and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 22 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SNN.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18SNN lead: Strengthening — the AIQ differential moved from 19 to 22 points over 30 sessions.
- Today
- SNN +22
- 48 vs 70
- 7 sessions ago
- SNN +22
- 49 vs 71
- 30 sessions ago
- SNN +19
- 44 vs 63
- 90 sessions ago
- SNN +30
- 30 vs 60
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 3 bearish / 1 neutral, conflicted
Only PACB
- Golden Cross Active — bullish, trend, long horizon (25.22%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (14.16%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
0 bullish / 2 bearish / 1 neutral
Only SNN
- Death Cross Active — bearish, trend, long horizon (7.77%)
- ADX Trend Strengthening — neutral, trend, medium horizon
Both carry 1 more signal that do not separate them: MACD Histogram Expanding Bearish.
PACB is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.62%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PACB closes the Value gap — currently 56 points behind, the largest single contributor to SNN's edge.
- 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3SNN starts generating bearish momentum or trend signals.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PACB leads on balance| Metric | PACB | SNN |
|---|---|---|
| Revenue growth (YoY) | 4% | -3.3% |
| EPS growth (YoY) | 14.3% | -7.7% |
| Gross margin | 34.5% | 68.2% |
| Operating margin | -99.6% | 16.7% |
| Return on equity (TTM) | 61.7% | 5.8% |
| Debt to equity | -11.49 | 0.73 |
Performance
PACB leads 5 of 6 windows| Metric | PACB | SNN |
|---|---|---|
| 1 week (5 sessions) | -13.1% | 0.4% |
| 1 month (20 sessions) | 13.3% | 7.6% |
| 3 months (63 sessions) | 62% | 5.4% |
| 6 months (126 sessions) | 75% | 5.9% |
| Year to date | 4.8% | -4.7% |
| 1 year (252 sessions) | 12.6% | -6.5% |
Technicals
PACB has the stronger structure| Metric | PACB | SNN |
|---|---|---|
| RSI (14) | 43.1 | 61.4 |
| ADX (14) | 27.4 | 28.9 |
| Price vs 50-day | -8.7% | 5.5% |
| Price vs 200-day | 22.4% | 1% |
| Volatility (1M, annualized) | 114.1% | 38.7% |
Risk
SNN is the more resilient| Metric | PACB | SNN |
|---|---|---|
| Beta | 2.1 | 0.29 |
| Sharpe ratio | 0.61 | -0.2 |
| Sortino ratio | 0.96 | -0.29 |
| Max drawdown | -58.4% | -28.4% |
| Current drawdown | -32.4% | -15.2% |
| Annualized volatility | 93.5% | 27.3% |
| Value at risk (95%) | -9% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, PACB or SNN?
On the Algovestiq AIQ Score, SNN is the stronger of the two as of Nov 18, 2026, scoring 70 against PACB's 48. The edge comes from value and risk resilience. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is PACB or SNN the better buy right now?
SNN carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 4 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor SNN over PACB?
The composite weights Quality, Value, Momentum and Risk Resilience. SNN leads Value by 56 points; SNN leads Risk Resilience by 51 points; SNN leads Quality by 41 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, PACB or SNN?
Analyst price targets imply +5.2% upside for PACB and +11.7% for SNN, so the Street currently favors SNN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, PACB or SNN?
SNN is the better-valued of the two on the peer-relative Value factor. SNN on the peer-relative Value factor, by 56 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, PACB or SNN?
PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, PACB or SNN?
PACB on the Momentum factor, by 24 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, PACB or SNN?
SNN is the more resilient of the two, so the other name carries the higher downside risk. SNN on Risk Resilience, by 51 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is PACB more profitable than SNN?
The profitability evidence is mixed: gross margin 34.5% vs 68.2%; operating margin -99.6% vs 16.7%; ttm roe 61.7% vs 5.8%. PACB leads on one measure and SNN on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is SNN's lead over PACB getting stronger or weaker?
SNN lead: Strengthening — the AIQ differential moved from 19 to 22 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.
What would change the PACB vs SNN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Value gap — currently 56 points behind, the largest single contributor to SNN's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; SNN starts generating bearish momentum or trend signals; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about PACB and SNN?
PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. SNN: 0 bullish / 2 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PACB is Golden Cross Active (bullish, long horizon). On SNN it is Death Cross Active (bearish, long horizon).
Compare PACB and SNN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.